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Short Report Two novel missense mutations in the myelin 
protein zero gene causes Charcot-Marie-Tooth 
type 2 and Déjérine-Sottas syndrome
Geir J Braathen*1,2, Jette C Sand2 and Michael B Russell1,2
Abstract
Background: The Charcot-Marie-Tooth (CMT) phenotype caused by mutation in the myelin protein zero (MPZ) gene 
varies considerably, from early onset and severe forms to late onset and milder forms. The mechanism is not well 
understood. The myelin protein zero (P0) mediates adhesion in the spiral wraps of the Schwann cell's myelin sheath. 
The crystalline structure of the extracellular domain of the myelin protein zero (P0ex) is known, while the 
transmembrane and intracellular structure is unknown.
Findings: One novel missense mutation caused a milder late onset CMT type 2, while the second missense mutation 
caused a severe early onset phenotype compatible with Déjérine-Sottas syndrome.
Conclusions: The phenotypic variation caused by different missense mutations in the MPZ gene is likely caused by 
different conformational changes of the MPZ protein which affects the functional tetramers. Severe changes of the 
MPZ protein cause dysfunctional tetramers and predominantly uncompacted myelin, i.e. the severe phenotypes 
congenital hypomyelinating neuropathy and Déjérine-Sottas syndrome, while milder changes cause the phenotypes 
CMT type 1 and 2.
Background
Charcot-Marie-Tooth (CMT) disease is characterized by
distal muscle wasting and weakness, sensory loss with
reduced tendon reflexes and foot deformities [1,2]. It is
the most common inherited disorder of the peripheral
nervous system with an estimated prevalence of 1 in
2,500 [3]. CMT is a heterogeneous disorder with respect
to clinical features, neurophysiology, pathophysiology
and genetics. The number of identified CMT genes is still
expanding. So far the majority of the CMT genes encodes
either neuronal or Schwann cell proteins [4]. However,
the most frequent autosomal recessive form of CMT is
caused by mutation in the glioside-induced differentia-
tion-associated protein-1 (GDAP1) gene, which is located
in the mitochondrial outer membrane and expressed in
both neurons and Schwann cells [5].
The myelin protein zero (MPZ) gene encodes a leader
peptide of 29 amino acids which is cleaved from the
remaining 219 amino acids before insertion in the myelin
sheath [6]. The myelin protein zero (P0) is post-transla-
tionally modified by additions of multiple sulphate, acyl
and phosphate groups and an N-linked oligosaccharide
[7,8]. P0 has an extracellular, a transmembrane and a cyto-
plasmic domain. It is the most abundant protein in the
myelin sheath of the peripheral nervous system [9]. The
extracellular domain from myelin protein zero protein
(P0ex) mediates homotypic adhesion, and it is essential
for the formation of the compact myelin layer of Schwann
cells [10,11]. It is included in the immunoglobulin super-
gene family, all members of which are involved in recog-
nition and/or adhesion. X-ray crystallography suggests
that P0ex emanate from the membrane surface as tetram-
ers that link to tetramers on the opposing membrane sur-
face, to result in the formation of networks of molecules
[12]. Knock-out mice without P0 expression develop a
severe dysmyelinating neuropathy with predominantly
uncompacted myelin [13].
The paper describes two novel missense mutations in
the MPZ gene, and discusses possible mechanism in rela-
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tion to the phenotypic variability caused by different mis-
sense mutations in the MPZ gene.
Methods
Patients
Norwegian patients with CMT disease were analyzed for
mutations in the MPZ gene. Affected were interviewed
and had a neurological examination. The Neuropathy
Impairment Score (NIS) and Charcot-Marie-Tooth dis-
ease neuropathy score (CMTNS) were used [14,15].
Nerve conduction velocities were recorded with surface
electrodes, while needles were used for electromyography
(EMG).
Genetics
DNA was extracted from leucocytes using QIAgen Flexi-
Gene kit (Düsseldorf, Germany). The sequences were
derived from the National Center for Biotechnology
Information (NP_000521 and NM_000530, MPZ). The
coding region of the MPZ gene as well as exon and intron
junctions were amplified using Eppendorf hotmaster taq
polymerase. The sequencing was carried out using for-
ward, reverse and internal primers, and BigDye Termina-
tor kit version 1.1 Applied Biosystems (Life Technologies,
Carslbad, CA, USA). Sequencing was performed using
Applied Biosystems ABI3130x1 Genetic analyzer and
aligned with the Sequencher programme (Gene Codes
Corporation, Ann Arbor, MI). Numbering nomenclature
used for the mutations includes the leader peptide of 29
amino acids.
Statistical analysis
SPSS for Windows version 14.0 was used for statistical
analysis.
Ethics
The study was approved by the Regional Committees for
Medical Research Ethics.
Results
Table 1 shows the demographics, clinical characteristics,
phenotypes and novel MPZ missense mutations in three
families. Additional file 1, table S2 shows the neurophysi-
ology in the three families. The affected from family 1
was an immigrant from the Philippines, while family 2
and 3 originated from the same county and carried the
same missense mutation. The affected in family 1 had
early onset and severe symptoms compatible with
Déjérine-Sottas syndrome (DSS), while affected in family
2 and 3 had late onset milder symptoms and axonal neu-
ropathy compatible with CMT type 2.
Discussion
Our main finding is the identification of two novel mis-
sense mutations in the MPZ gene. The phenotype/geno-
type correlation is likely in family 1, while three affected
all carried the mutation in family 2 and 3. Unfortunately
we did not have DNA from the unaffected family mem-
bers. However, the literature describes other missense
mutations in the MPZ gene that affects the same codons
as our novel missense mutations [6,16-18]. Change of
nucleotide 103 was not found in 100 unrelated controls,
and change of nucleotide 368 was not found in 80 unre-
lated controls [16,18]. Thus, we suggest that the novel
MPZ missense mutations are disease causing rather than
polymorphisms.
Phenotype
Missense mutations in the MPZ gene account for about
2% of patients with CMT type 1 [18]. The phenotype var-
ies considerably from early to late age at onset. Clinically
missense mutations in the MPZ gene can cause congeni-
tal hypomyelinating neuropathy (CH), DSS, CMT type 1,
CMT type 2 and intermediate CMT [6,16-22]. The phe-
notypes CH and DSS are characterized by early onset and
severe symptomatology, while the other phenotypes have
a later age at onset and milder symptomatology. Our
patients had phenotypes compatible with DSS and CMT
type 2.
Phenotype related to MPZ protein structure
Our patient with DSS had a Gly123Asp amino acid sub-
stitution. Another patient with DSS had a Gly123Cys,
while a patient with CMT type 1 had a Gly123Ser amino
acid substitution [6,18]. Details about the patient with
CMT type 1 are unfortunately not available. Ser has a
structure that is much more similar to Gly than both Asp
and Cys. Thus, the Gly123Ser amino acid change may
cause less conformational changes of P0  than the
Gly123Asp and Gly123Cys amino acid change. Similarly,
missense mutations in the codon that include residue
number 124 can cause CMT type 1 or CMT type 2
[19,21,22]. This is probably due to the characteristics of
the specific amino acid substitution and the conforma-
tional changes of the MPZ protein. Our patients with
CMT type 2 had Asp35Asn amino acid substitution. Asp
and Asn has very similar structure and probably only
causes minor conformational changes of P0, even though
Asp is negatively charged and Asn is polar. Asp35Tyr
causes intermediate CMT, CMT type 1 and CMT type 2
[16,17]. Tyr, a polar amino acid, has a hydroxyphenyl
group that replace Asp charged side chain. The confor-
mational change is likely to be small.
HeLa cells tranfected with two late onset and two early
onset MPZ mutations showed that the two late onset
mutations had normal transportation of the P0 to the cell
membrane and moderately reduced MPZ-mediated
intercellular adhesion, while the two early onset muta-
tions had different patterns [23]. One early onset type wasBraathen et al. BMC Research Notes 2010, 3:99
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Table 1: Demographics, clinical characteristics, neurophysiology, phenotype and missense mutation for the three 
families.
Family 1 2 3
Family member Father Daughter
Demographic
Sex 
Age at onset 2 70 29 56




c r a n i a l  n e r v e s 0000
Muscle weakness 24 26 15 4
Reflexes 16 16 2 4
Sensation 24 6 6 2




Sensory symptoms 3 0 3 3
Motor symptoms
L e g s 4111
A r m s 1000
Pin sensibility 4 3 3 3
Vibration 4 4 3 -
Strength
L e g s 1314
A r m s 3100
Ulnar/median CMAP 2 - 0 1
Ulnar/median SNAP 4 - 3 3
Total CMTNS score 26 12 14 15
Ataxia Marked Slight - -
Romberg Positive - Positive -
Pes cavus Present - Present Present









Missense mutation 368G>A 103G>A 103G>A 103G>A
Amino acid change Gly123Asp Asp35Asn Asp35Asn Asp35AsnBraathen et al. BMC Research Notes 2010, 3:99
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correctly glycosylated and trafficked to the plasma mem-
brane, but intercellular adhesion was strongly affected,
while the other early onset type caused by deletion in the
gene showed that the transcripted P0 was retained within
the cytoplasm with secondary reduced adhesion. The
Ser63del causes a demyelinating neuropathy in transgenic
mice, similar to the Ser63del causes a CMT type 1 in
humans [24-26]. Interestingly, the P0 Ser63del is retained
in the endoplasmic reticulum, and it fails to be incorpo-
rated into myelin [24,25]. These are very interesting
mechanisms which are not directly related to the confor-
mational change of the P0. The retained P0 might be the
mechanism that causes congenital hypomyelinating neu-
ropathy (CH). The literature provides several examples
on allelic heterogeneity, i.e. mutations in one gene can
cause different phenotypes. An example is mutations in
the CACNA1A gene, which causes familial hemiplegic
migraine (FHM-1), episodic ataxia (EA-2) or spinocere-
bellar ataxia (SCA-6) [27,28]. FHM-1 is characterized by
sensory and motor aura followed by headache. The FHM-
1 families show both intra- and interfamilial variability.
Affected from some FHM-1 families experience severe
hemiplegic attacks, cerebral oedema and life threatening
coma due to minor head trauma. The more common
Charcot-Marie-Tooth genes identified so far show both
locus and allelic heterogeneity. The allelic heterogeneity
in the MPZ gene is characterized by different types of
neuropathy, in contrast to different disorders caused by
mutations in the CACNA1A gene. At present it is antici-
pated that four P0 proteins form a tetramer and link to a
tetramer of the opposed membrane. To our knowledge
expression of the MPZ alleles is unknown. If one allele is
expressed per cell, it will either be a wild type or changed
P0. However, if both alleles are expressed equally,
tetramer assembly would statistically be in the order 1:16,
4:16, 6:16, 4:16, 1:16 for the different combinations of
wild type and changed P0. Thus, only 1:256 (1:162) will be
normal tetramers that can link together. A sural nerve
biopsy of a patient with CH caused by a mutation in P0
presented a characteristic picture of non-myelinated and
poorly myelinated axons with basal lamina onion bulbs
and lack of myelin breakdown products [29]. The histol-
o g y  s u p p o r t s  t h a t  b o t h  a l l e l e s ,  i . e .  t h e  w i l d  t y p e  a n d
mutated allele, are expressed in each Schwann cell. If only
one allele was expressed per cell, one would expect to
observe both normal and abnormal Schwann cell histol-
ogy, i.e. normal and abnormal myelination along the
axon. The assembly of different tetramers may also
explain the intrafamilial variation of symptoms and age at
onset [16,24]. Even a concordant monozygotic twin pair
was described with different progression, classified as
Roussy-Lévy variant of CMT1 and CMT1, respectively
[30]. We cannot exclude the importance of environmen-
tal factor with certainty. However we do not think the
environment has a crucial role given proper nutrition and
exclusion of other neuropathy inducing factors.
Conclusions
We suggest that the phenotypic variation caused by dif-
ferent missense mutation in the MPZ  gene is closely
linked to the effects on the MPZ protein tetramers, which
is crucial for axonal myelination.
Additional material
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
GJB acquired the material, conceived the study, participated in the design of
the study and drafted the manuscript. JCS carried out the molecular genetic
studies and the sequence alignment. MBR conceived the study, participated in
the design of the study and drafted the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The study was financially supported by University of Oslo, Faculty Division 
Akershus University Hospital, Helse Øst, Sentralsykehuset i Akershus and 
Nansen Foundation.
Author Details
1Faculty Division Akershus University Hospital, University of Oslo, 1474 
Nordbyhagen, Oslo, Norway and 2Head and Neck Research Group, Research 
Centre, Akershus University Hospital, 1478 Lørenskog, Oslo, Norway
References
1. Charcot JM, Marie P: Sur une form particulière d'atrophie musculaire 
progressive, souvant familiale, debutant par les pieds et les jambes, et 
atteignant plus tard les mains.  Rev Méd Paris 1886, 6:97-138.
2. Tooth HH: The Peroneal Type of Progressive Muscular Atrophy.  London: 
H. K. Lewis pub; 1886. 
3. Skre H: Genetic and clinical aspects of Charcot-Marie-Tooth's disease.  
Clin Genet 1974, 6:98-118.
4. Shy ME, Garbern JY, Kamholz J: Hereditary motor and sensory 
neuropathies; a biological perspective.  Lancet Neurol 2002, 1:110-118.
5. Niemann A, Ruegg M, La Padula V, Schenone A, Suter U: Ganglioside-
induced differentiation-associated protein-1 is a regulator of the 
mitochondrial network:new implications for Charcot-Marie-Tooth 
disease.  J Cell Biol 2005, 170:1067-1078.
6. Inherited Peripheral Neuropathies Mutation Database   [http://
www.molgen.ua.ac.be/CMTMutations/]. (accessed 09/02/2010)
7. D'Urso D, Brophy PJ, Staugaitis SM, Gillespie CS, Frey AB, Stempak JG, 
Colman DR: Protein zero of peripheral nerve myelin:biosynthesis, 
membrane insertion, and evidence for homotypic interaction.  Neuron 
1990, 4:449-460.
8. Eichberg J, Iyer S: Phosphorylation of myelin protein:recent advances.  
Neurochem Res 1996, 21:527-535.
9. Lemke G: Unwrapping the genes of myelin.  Neuron 1988, 1:535-543.
10. Lemke G, Axel R: Isolation and sequence of a cDNA encoding the major 
structural protein of peripheral myelin.  Cell 1985, 40:501-508.
11. Filbin MT, Walsh FS, Trapp BD, Pizzey JA, Tennekoon GI: Role of myelin P0 
protein as a homophilic adhesion molecule.  Nature 1990, 344:871-872.
Additional file 1 Table S2. Neurophysiology in patients with Charcot-
Marie-Tooth disease caused by point mutations in the MPZ.
Received: 25 September 2009 Accepted: 12 April 2010 
Published: 12 April 2010
This article is available from: http://www.biomedcentral.com/1756-0500/3/99 © 2010 Braathen et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Research Notes 2010, 3:99Braathen et al. BMC Research Notes 2010, 3:99
http://www.biomedcentral.com/1756-0500/3/99
Page 5 of 5
12. Shapiro L, Doyle JP, Hensley P, Colman DR, Hendrickson WA: Crystal 
structure of the extracellular domain from P0, the major structural 
protein of peripheral nerve myelin.  Neuron 1996, 17:435-449.
13. Xu W, Manichella D, Jiang H, Vallat JM, Lilien J, Baron P, Scarlato G, 
Kamholz J, Shy ME: Absence of P0 leads to the dysregulation of myelin 
gene expression and myelin morphogenesis.  J Neurosci Res 2000, 
60:714-724.
14. Dyck PJ, Turner DW, Davies JL, O'Brien PC, Dyck PJ, Rask CA: Electronic 
case-report forms of symptoms and impairments of peripheral 
neuropathy.  Can J Neurol Sci 2002, 29:258-266.
15. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, 
Reilly M: Reliability and validity of the CMT neuropathy score as a 
measure of disability.  Neurology 2005, 64:1209-1214.
16. Mastaglia FL, Nowak KJ, Stell R, Phillips BA, Edmondston JE, Dorosz SM, 
Wilton SD, Hallmayer J, Kakulas BA, Laing NG: Novel mutation in the 
myelin protein zero gene in a family with intermediate hereditary 
motor and sensory neuropathy.  J Neurol Neurosurg Psychiatry 1999, 
67:174-179.
17. Hattori N, Yamamoto M, Yoshihara T, Koike H, Nakagawa M, Yoshikawa H, 
Ohnishi A, Hayasaka K, Onodera O, Baba M, Yasuda H, Saito T, Nakashima 
K, Kira J, Kaji R, Oka N, Sobue G, Study Group for Hereditary Neuropathy in 
Japan: Demyelinating and axonal features of Charcot-Marie-Tooth 
disease with mutations of myelin-related proteins (PMP22, MPZ and 
Cx32):a clinicopathological study of 205 Japanese patients.  Brain 2003, 
126:134-151.
18. Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K, Russo P, 
Kennedy S, Teebi AS, Scavina M, Williams LL, Mancias P, Butler IJ, Krajewski 
K, Shy M, Lupski JR: Charcot-Marie-Tooth disease and related 
neuropathies:mutation distribution and genotype-phenotype 
correlation.  Ann Neurol 2002, 51:190-201.
19. De Jonghe P, Timmerman V, Ceuterick C, Nelis E, De Vriendt E, Löfgren A, 
Vercruyssen A, Verellen C, Van Maldergem L, Martin JJ, Van Broeckhoven C: 
The Thr124Met mutation in the peripheral myelin protein zero MPZ 
gene is associated with a clinically distinct Charcot-Marie-Tooth 
phenotype.  Brain 1999, 122:281-290.
20. Shy ME, Jáni A, Krajewski K, Grandis M, Lewis RA, Li J, Shy RR, Balsamo J, 
Lilien J, Garbern JY, Kamholz J: Phenotypic clustering in MPZ mutations.  
Brain 2004, 127:371-384.
21. Schiavon F, Rampazzo A, Merlini L, Angelini C, Mostacciuolo ML: 
Mutations of the same sequence of the myelin P0 gene causing two 
different phenotypes.  Hum Mutat 1998:S217-219.
22. Chapon F, Latour P, Diraison P, Schaeffer S, Vandenberghe A: Axonal 
phenotype of Charcot-Marie-Tooth disease associated with a mutation 
in the myelin protein zero gene.  J Neurol Neurosurg Psychiatry 1999, 
66:779-782.
23. Grandis M, Vigo T, Passalacqua M, Jain M, Scazzola S, La Padula V, Brucal M, 
Benvenuto F, Nobbio L, Cadoni A, Mancardi GL, Kamholz J, Shy ME, 
Schenone A: Different cellular and molecular mechanisms for early and 
late-onset myelin protein zero mutations.  Hum Mol Genet 
2008:1877-1889.
24. Wrabetz L, D'Antonio M, Pennuto M, Dati G, Tinelli E, Fratta P, Previtali S, 
Imperiale D, Zielasek J, Toyka K, Avila RL, Kirschner DA, Messing A, Feltri 
ML, Quattrini A: Different intracellular pathomechanisms produce 
diverse Myelin Protein Zero neuropathies in transgenic mice.  J Neurosci 
2006, 26:2358-2368.
25. Pennuto M, Tinelli E, Malaguti M, Del Carro U, D'Antonio M, Ron D, 
Quattrini A, Feltri ML, Wrabetz L: Ablation of the UPR-mediator CHOP 
restores motor function and reduces demyelination in Charcot-Marie-
Tooth 1B mice.  Neuron 2008, 57:393-405.
26. Kulkens T, Bolhuis PA, Wolterman RA, Kemp S, te Nijenhuis S, Valentijn LJ, 
Hensels GW, Jennekens FG, de Visser M, Hoogendijk JE, Baas F: Deletion 
of the serine 34 codon from the major peripheral myelin protein P0 
gene in Charcot-Marie-Tooth disease type 1B.  Nat Genet 1993, 5:35-39.
27. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman 
SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, 
Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR: Familial 
hemiplegic migraine and episodic ataxia type-2 are caused by 
mutations in the Ca2+ channel gene CACNL1A4.  Cell 1996, 87:543-552.
28. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, 
Dobyns WB, Subramony SH, Zoghbi HY, Lee CC: Autosomal dominant 
cerebellar ataxia (SCA6) associated with small polyglutamine 
expansions in the alpha 1A-voltage-dependent calcium channel.  Nat 
Genet 1997, 15:62-69.
29. Kochanski A, Drac H, Kabziñska D, Ryniewicz B, Rowiñska-Marciñska K, 
Nowakowski A, Hausmanowa-Petrusewicz I: A novel MPZ gene mutation 
in congenital neuropathy with hypomyelination.  Neurology 2004, 
62:2122-2123.
30. Marques W Jr, Hanna MG, Marques SR, Sweeney MG, Thomas PK, Wood 
NW: Phenotypic variation of a new P0 mutation in genetically identical 
twins.  J Neurol 1999, 246:596-599.
doi: 10.1186/1756-0500-3-99
Cite this article as: Braathen et al., Two novel missense mutations in the 
myelin protein zero gene causes Charcot-Marie-Tooth type 2 and Déjérine-
Sottas syndrome BMC Research Notes 2010, 3:99